{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nal-IRI&page=2", "query": { "intervention": "Nal-IRI", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nal-IRI&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T11:11:26.921Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03739801", "title": "MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Unresectable Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Liposomal Irinotecan", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-04-06", "completion_date": "2023-04-06", "has_results": false, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-09-28T11:11:26.921Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739801" }, { "nct_id": "NCT07340151", "title": "Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adenocarcinoma of the Pancreas" ], "interventions": [ { "name": "Surgical resection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 40, "start_date": "2026-03-02", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-09-28T11:11:26.921Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07340151" }, { "nct_id": "NCT04901702", "title": "Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Solid Tumor", "Recurrent Ewing Sarcoma", "Recurrent Hepatoblastoma", "Recurrent Malignant Germ Cell Tumor", "Recurrent Malignant Solid Neoplasm", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma", "Recurrent Peripheral Primitive Neuroectodermal Tumor", "Recurrent Rhabdoid Tumor", "Recurrent Rhabdomyosarcoma", "Recurrent Soft Tissue Sarcoma", "Recurrent Wilms Tumor", "Refractory Ewing Sarcoma", "Refractory Hepatoblastoma", "Refractory Malignant Germ Cell Tumor", "Refractory Malignant Solid Neoplasm", "Refractory Neuroblastoma", "Refractory Osteosarcoma", "Refractory Peripheral Primitive Neuroectodermal Tumor", "Refractory Rhabdoid Tumor", "Refractory Rhabdomyosarcoma", "Refractory Soft Tissue Sarcoma" ], "interventions": [ { "name": "Onivyde", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Months to 30 Years" }, "enrollment_count": 90, "start_date": "2021-06-09", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-09-28T11:11:26.921Z", "location_count": 7, "location_summary": "Palo Alto, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04901702" }, { "nct_id": "NCT03861702", "title": "Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Pancreatic Carcinoma(LAPC)" ], "interventions": [ { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "Liposomal Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nelson Yee", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2020-09-02", "completion_date": "2024-09-27", "has_results": true, "last_update_posted_date": "2025-04-18", "last_synced_at": "2026-09-28T11:11:26.921Z", "location_count": 4, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03861702" }, { "nct_id": "NCT04656041", "title": "Folfox+Irinotecan+Chemort In Esophageal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Junction Adenocarcinoma", "Esophagogastric Cancer" ], "interventions": [ { "name": "FOLFOX/ nal-IRI", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Proton Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-06-29", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-09-28T11:11:26.921Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Newton, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Newton", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04656041" }, { "nct_id": "NCT03703063", "title": "Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab paclitaxel", "type": "DRUG" }, { "name": "Onivyde", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fu", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Benaroya Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-09-17", "completion_date": "2022-09-17", "has_results": false, "last_update_posted_date": "2021-01-27", "last_synced_at": "2026-09-28T11:11:26.921Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03703063" }, { "nct_id": "NCT07076212", "title": "Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Pancreatic Adenocarcinoma", "Locally Advanced Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Liposomal Irinotecan", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Gemcitabine (mg/m²)", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2026-04-02", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-09-28T11:11:26.921Z", "location_count": 2, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07076212" }, { "nct_id": "NCT07060014", "title": "NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Small Intestine Cancer", "Appendiceal Cancers" ], "interventions": [ { "name": "Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Methodist Hospital Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2026-09-18", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-09-28T11:11:26.921Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07060014" }, { "nct_id": "NCT04731467", "title": "A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Non Small Cell Lung Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Papillary Thyroid Cancer", "Melanoma", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "CM-24 and Nivolumab - Dose Escalation", "type": "DRUG" }, { "name": "CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion", "type": "DRUG" }, { "name": "CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion", "type": "DRUG" }, { "name": "Nivolumab, Nab paclitaxel and Gemcitabine - Expansion", "type": "DRUG" }, { "name": "Nivolumab and Nal-IRI/5-FU/LV - Expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Famewave Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2021-03-19", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-09-28T11:11:26.921Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • New Haven, Connecticut + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04731467" }, { "nct_id": "NCT06736717", "title": "Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Onvansertib", "type": "DRUG" }, { "name": "NALIRIFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2025-02-17", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-09-28T11:11:26.921Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06736717" } ] }